Comparative Pharmacology
Head-to-head clinical analysis: MONOCID versus SUPRAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MONOCID versus SUPRAX.
MONOCID vs SUPRAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Cefixime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
1 g intramuscularly or intravenously every 24 hours; for severe infections, 2 g every 24 hours.
400 mg orally once daily or 200 mg orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 4-5 hours (prolonged to 12-24 hours in severe renal impairment; dosing adjustment recommended for CrCl <50 mL/min).
Terminal elimination half-life: 3-4 hours in normal renal function; prolonged to 11-15 hours in severe renal impairment (CrCl <20 mL/min).
Renal: ~90% unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: ~5% (cefonicid undergoes minimal hepatic metabolism; ~4% excreted in feces as parent drug and metabolites).
Renal: 50-55% unchanged in urine; biliary/fecal: 10-20% (biliary excretion); remainder metabolized or excreted via feces.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic